Exhibit 10.33
EXECUTION COPY
LICENSE AND COLLABORATION AGREEMENT
between
Myriad Genetics, Inc.
and
H. Lundbeck A/S
Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as amended.
This License and Collaboration Agreement (hereinafter referred to as the “Agreement ”) is made and
entered into as of May 21, 2008 (the “Effective Date” ) between Myriad Genetics, Inc., a corporation
organized and existing under the laws of Delaware, with its principal business office located at 320 Wakara
Way, Salt Lake City, Utah 84108 USA (hereinafter referred to as “Myriad” ), and H. Lundbeck A/S, with a
principal business office located at Ottiliavej 9, 2500 Valby, Denmark (hereinafter referred to as “Lundbeck”
). Each of Myriad and Lundbeck may be referred to in this Agreement as a “Party” and together as the
“Parties” .
WITNESSETH
WHEREAS, Myriad controls certain rights to develop, manufacture, market, sell and out-license the
Compound and Product (each as defined below) based on certain patents and know-how in-licensed from
Encore (as defined below), certain patents and know-how in-licensed from certain other Third Parties (as
defined below), and certain patents and know-how owned by Myriad relating to the Compound or Product
covering the treatment of Alzheimer’s disease and other indications and applications, as specified herein;
WHEREAS, Lundbeck is engaged in the research, development, marketing, manufacture and distribution
of pharmaceutical compounds used in treating or preventing human diseases and conditions;
WHEREAS, Myriad wishes to out-license certain rights to the Compound and Product to Lundbeck for the
treatment of Alzheimer’s disease and for other indications;
WHEREAS, Lundbeck now desires to participate in the research, Development, manufacture and
Commercialisation of the Compound and Product for sale in the Territory;
NOW TH